# BRCA agent answers (brca_v2) — readable copy

Generated from `eval/traces/brca_v2_agent/`. For each patient: the somatic mutations the agent saw, the final answer as shown to users, and every verifier-checked claim with its citations written out. Edge IDs (`E…`) are rows in `data/processed/edges.parquet`; `pt:` IDs are the patient's own data; `rank:` IDs are model outputs (cohort-relative, not evidence).

Question asked: *"What drives this patient's tumor biology, and what would you target?"*

Caveats: tumour-only mutation calls; protein z-scores are relative to the BRCA cohort (no matched normal); no ER/PR/HER2 status recorded; no outcome model for BRCA. These 5 patients are not a blind test.

## 11BR060

**Somatic mutations (2):** PDE4DIP p.G2081S, TP53 p.T125T

**Verifier:** 32 supported, 1 hypothesis, 6 removed (of 39 claims); 7 caveat/experiment lines not scored.

### Answer

**Summary**
Patient 11BR060’s tumor shows a HER2-enriched profile: ERBB2 (HER2) protein is strongly up‑regulated (z=3.53) together with its co‑amplified partner GRB7 (z=3.37) and multiple ERBB2‑signaling pathways (PLCG1, GRB7 events, drug‑inhibition and resistance pathways) [E3799008, E3799010, E3799023, E3799026, E3799035]. A somatic TP53 p.T125T mutation is present [pt:11BR060:somatic_mutation:NCBIGene:7157], and the curated breast‑carcinoma mechanism links TP53 loss to EMT, dissemination and immune evasion [PMID:23000897, PMID:21336307]. Additional high‑z drivers include LIMK2 (z=4.59, cytoskeletal/metastasis), EIF2AK2/PKR (z=3.08, stress/translation), RB1 (z=3.05, cell‑cycle), and PNMT (z=4.13, catecholamine synthesis) [pt:11BR060:protein_up:NCBIGene:3985, pt:11BR060:protein_up:NCBIGene:5610, pt:11BR060:protein_up:NCBIGene:5925, pt:11BR060:protein_up:NCBIGene:5409].

**Evidence paths**
- ERBB2 up → ERBB2 signaling pathways (PLCG1, GRB7, drug inhibition/resistance) [E3799008, E3799010, E3799023, E3799026, E3799035]
- TP53 somatic mutation → TP53 loss mechanism → EMT → organ tropism → immune evasion [PMID:23000897, PMID:21336307]
- LIMK2 up → mitotic spindle component [E3628890]
- EIF2AK2 up → translation initiation regulation, NLRP3 inflammasome [E3773221, E3773217]
- PNMT up → catecholamine biosynthesis [E3812841]
- PDE4DIP p.G2081S mutation → centrosome/myofibril protein interactions [E3609097, E3613921, E212312, E166352, E176852, E320621, E259497]

**Mechanism**
1. ER/HER2 receptor heterogeneity drives subtype diversity [PMID:27349894]
2. TP53 loss of function enables EMT-driven dissemination [PMID:23000897, PMID:21336307]
5. PIK3CA mutations (not seen here) can constitutively activate PI3K‑AKT‑mTOR [PMID:15647370]
6. Endocrine resistance, angiogenic outgrowth, and cell survival/proliferation are additional breast‑carcinoma chains [E8271407, E8137940, E8271406]

**Targets / drugs** (cited rationale, not proof of efficacy)
1. **ERBB2 (HER2)** – up‑regulated z=3.53 [pt:11BR060:protein_up:NCBIGene:2064]
   - **Pertuzumab** – drug→ERBB2 [E331495], indication HER2+ breast cancer [E387024, E8202833]
   - **Trastuzumab** – drug→ERBB2 [E331489], indication HER2+ breast cancer [E387026, E8202831]
   - **Trastuzumab emtansine** – drug→ERBB2 [E331492], indication HER2+ breast cancer [E387027]
   - **Tucatinib** – drug→ERBB2 [E322197], treats HER2+ breast cancer [E8202837]
   - **Lapatinib** – drug→ERBB2 [E331490], indication HER2+ breast cancer [E387025]
   - **Brigatinib** – drug→ERBB2 [E331499]
   - **Zanubrutinib** – drug→ERBB2 [E331501]; model‑ranked #2 [rank:11BR060:drug:DRUGBANK:DB15035]
2. **LIMK2** – up‑regulated z=4.59 [pt:11BR060:protein_up:NCBIGene:3985]
   - **Fostamatinib** – drug→LIMK2 [E343064]; also hits ERBB2 [E331498], EIF2AK2 [E343042], MAP4K2 [E343079]; model‑ranked #1 [rank:11BR060:drug:DRUGBANK:DB12010]
3. **EIF2AK2 (PKR)** – up‑regulated z=3.08 [pt:11BR060:protein_up:NCBIGene:5610]
   - **Fostamatinib** – drug→EIF2AK2 [E343042]
4. **PNMT** – up‑regulated z=4.13 [pt:11BR060:protein_up:NCBIGene:5409]
5. **TP53** – somatic mutation p.T125T [pt:11BR060:somatic_mutation:NCBIGene:7157]
   - **Acetylsalicylic acid** – drug→TP53 [E337995]
   - **Zinc acetate** – drug→TP53 [E338000]
6. **RB1** – up‑regulated z=3.05 [pt:11BR060:protein_up:NCBIGene:5925]
   - **Insulin human** – drug→RB1 [E336879]
7. **Model‑ranked kinase inhibitors** (tumor‑protein driven, not direct target matches): Ruxolitinib [rank:11BR060:drug:DRUGBANK:DB08877], Radotinib [rank:11BR060:drug:DRUGBANK:DB12323], Bosutinib [rank:11BR060:drug:DRUGBANK:DB06616], Dasatinib [rank:11BR060:drug:DRUGBANK:DB01254], Fasudil [rank:11BR060:drug:DRUGBANK:DB08162].

**Testable hypothesis**
Hypothesis: The co‑overexpression of ERBB2, GRB7, and LIMK2 creates a HER2‑driven, cytoskeleton‑remodeling state that is uniquely sensitive to combined HER2 blockade (e.g., pertuzumab + trastuzumab) plus LIMK2 inhibition (fostamatinib).
Experiment: Treat 11BR060‑derived organoids or xenografts with pertuzumab + trastuzumab ± fostamatinib; measure p‑ERBB2, p‑LIMK2/cofilin, invasion, and viability.

**Caveats**
- Protein z‑scores are relative to the tumor cohort (no matched normal); “up” means higher than other tumors, not necessarily absolute overexpression.
- Somatic mutations are tumor‑only; germline status unknown.
- Drug‑target edges are from PrimeKG; indication edges are from PrimeKG or DisMech (may reflect trials, not approvals).
- GNN‑A risk model is unavailable for BRCA; no stage/grade prediction.
- Model‑ranked drugs reflect tumor‑protein similarity to training cohort, not clinical response data.
- No clinical outcome, treatment history, or hormone‑receptor status is recorded for this patient.

_Verifier: removed 6 claim(s) that had no supporting edge or PMID._

### Claims and what each citation is

- ✅ supported — Patient 11BR060’s tumor shows a HER2-enriched profile: ERBB2 (HER2) protein is strongly up‑regulated (z=3.53) together with its co‑amplified partner GRB7 (z=3.37) and multiple ERBB2‑signaling pathways (PLCG1, GRB7 events, drug‑inhibition and resistance pathways).
    - `E3799008` ERBB2 —pathway_protein→ PLCG1 events in ERBB2 signaling
    - `E3799010` ERBB2 —pathway_protein→ GRB7 events in ERBB2 signaling
    - `E3799023` ERBB2 —pathway_protein→ Drug-mediated inhibition of ERBB2 signaling
    - `E3799026` ERBB2 —pathway_protein→ Resistance of ERBB2 KD mutants to sapitinib
    - `E3799035` ERBB2 —pathway_protein→ Drug resistance in ERBB2 TMD/JMD mutants
- ✅ supported — A somatic TP53 p.T125T mutation is present, and the curated breast‑carcinoma mechanism links TP53 loss to EMT, dissemination and immune evasion.
    - `pt:11BR060:somatic_mutation:NCBIGene:7157` patient: TP53 p.T125T (somatic)
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
- ✅ supported — Additional high‑z drivers include LIMK2 (z=4.59, cytoskeletal/metastasis), EIF2AK2/PKR (z=3.08, stress/translation), RB1 (z=3.05, cell‑cycle), and PNMT (z=4.13, catecholamine synthesis).
    - `pt:11BR060:protein_up:NCBIGene:3985` patient: LIMK2 protein up (z=4.6)
    - `pt:11BR060:protein_up:NCBIGene:5610` patient: EIF2AK2 protein up (z=3.1)
    - `pt:11BR060:protein_up:NCBIGene:5925` patient: RB1 protein up (z=3.1)
    - `pt:11BR060:protein_up:NCBIGene:5409` patient: PNMT protein up (z=4.1)
- ❌ removed — The GNN‑A risk model is not available for BRCA, so no stage estimate is provided.
- ✅ supported — ERBB2 up → ERBB2 signaling pathways (PLCG1, GRB7, drug inhibition/resistance)
    - `E3799008` ERBB2 —pathway_protein→ PLCG1 events in ERBB2 signaling
    - `E3799010` ERBB2 —pathway_protein→ GRB7 events in ERBB2 signaling
    - `E3799023` ERBB2 —pathway_protein→ Drug-mediated inhibition of ERBB2 signaling
    - `E3799026` ERBB2 —pathway_protein→ Resistance of ERBB2 KD mutants to sapitinib
    - `E3799035` ERBB2 —pathway_protein→ Drug resistance in ERBB2 TMD/JMD mutants
- ✅ supported — TP53 somatic mutation → TP53 loss mechanism → EMT → organ tropism → immune evasion
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
- ✅ supported — LIMK2 up → mitotic spindle component
    - `E3628890` LIMK2 —cellcomp_protein→ mitotic spindle
- ✅ supported — EIF2AK2 up → translation initiation regulation, NLRP3 inflammasome
    - `E3773221` EIF2AK2 —bioprocess_protein→ regulation of NLRP3 inflammasome complex assembly
    - `E3773217` EIF2AK2 —bioprocess_protein→ regulation of translational initiation by eIF2 alpha phosphorylation
- ❌ removed — RB1 up → G1/S transition, E2F binding, chromatin
    - `E3819223` RB1 —pathway_protein→ Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
    - `E3791682` Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects —pathway_pathway→ Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
    - `E3611818` RB1 —cellcomp_protein→ chromatin
    - ⚠ cited edge doesn't name anything in the sentence: E3791682
- ✅ supported — PNMT up → catecholamine biosynthesis
    - `E3812841` PNMT —pathway_protein→ Catecholamine biosynthesis
- ✅ supported — PDE4DIP p.G2081S mutation → centrosome/myofibril protein interactions
    - `E3609097` PDE4DIP —cellcomp_protein→ centrosome
    - `E3613921` PDE4DIP —cellcomp_protein→ myofibril
    - `E212312` PDE4DIP —protein_protein→ ARHGAP45
    - `E166352` PDE4DIP —protein_protein→ NCCRP1
    - `E176852` PDE4DIP —protein_protein→ LIN37
    - `E320621` PDE4DIP —protein_protein→ NIBAN2
    - `E259497` PRKACG —protein_protein→ PDE4DIP
- ✅ supported — ER/HER2 receptor heterogeneity drives subtype diversity
    - [PMID:27349894](https://pubmed.ncbi.nlm.nih.gov/27349894/)
- ✅ supported — TP53 loss of function enables EMT-driven dissemination
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
- ❌ removed — EMT-driven dissemination leads to organ‑specific tropism
- ❌ removed — Metastatic niches acquire immune‑evasion capabilities
- ✅ supported — PIK3CA mutations (not seen here) can constitutively activate PI3K‑AKT‑mTOR
    - [PMID:15647370](https://pubmed.ncbi.nlm.nih.gov/15647370/)
- ✅ supported — Endocrine resistance, angiogenic outgrowth, and cell survival/proliferation are additional breast‑carcinoma chains
    - `E8271407` breast carcinoma —dm_disease_has_basis_in→ Endocrine Resistance
    - `E8137940` breast carcinoma —dm_disease_has_basis_in→ Angiogenic Outgrowth
    - `E8271406` breast carcinoma —dm_disease_has_basis_in→ Cell Survival and Proliferation
- ✅ supported — **ERBB2 (HER2)** – up‑regulated z=3.53
    - `pt:11BR060:protein_up:NCBIGene:2064` patient: ERBB2 protein up (z=3.5)
- ✅ supported — **Pertuzumab** – drug→ERBB2, indication HER2+ breast cancer
    - `E331495` Pertuzumab —drug_protein→ ERBB2
    - `E387024` Pertuzumab —indication→ HER2 positive breast carcinoma
    - `E8202833` Pertuzumab —dm_treats_or_applied_or_studied_to_treat→ HER2 positive breast carcinoma
- ✅ supported — **Trastuzumab** – drug→ERBB2, indication HER2+ breast cancer
    - `E331489` Trastuzumab —drug_protein→ ERBB2
    - `E387026` Trastuzumab —indication→ HER2 positive breast carcinoma
    - `E8202831` Trastuzumab —dm_treats_or_applied_or_studied_to_treat→ HER2 positive breast carcinoma
- ✅ supported — **Trastuzumab emtansine** – drug→ERBB2, indication HER2+ breast cancer
    - `E331492` Trastuzumab emtansine —drug_protein→ ERBB2
    - `E387027` Trastuzumab emtansine —indication→ HER2 positive breast carcinoma
- ✅ supported — **Tucatinib** – drug→ERBB2, treats HER2+ breast cancer
    - `E322197` Tucatinib —drug_protein→ ERBB2
    - `E8202837` Tucatinib —dm_treats_or_applied_or_studied_to_treat→ HER2 positive breast carcinoma
- ✅ supported — **Lapatinib** – drug→ERBB2, indication HER2+ breast cancer
    - `E331490` Lapatinib —drug_protein→ ERBB2
    - `E387025` Lapatinib —indication→ HER2 positive breast carcinoma
- ✅ supported — **Brigatinib** – drug→ERBB2
    - `E331499` Brigatinib —drug_protein→ ERBB2
- ✅ supported — **Zanubrutinib** – drug→ERBB2; model‑ranked #2
    - `E331501` Zanubrutinib —drug_protein→ ERBB2
    - `rank:11BR060:drug:DRUGBANK:DB15035` model rank: Zanubrutinib (#2 drug)
- ✅ supported — **LIMK2** – up‑regulated z=4.59
    - `pt:11BR060:protein_up:NCBIGene:3985` patient: LIMK2 protein up (z=4.6)
- ✅ supported — **Fostamatinib** – drug→LIMK2; also hits ERBB2, EIF2AK2, MAP4K2; model‑ranked #1
    - `E343064` Fostamatinib —drug_protein→ LIMK2
    - `E331498` Fostamatinib —drug_protein→ ERBB2
    - `E343042` Fostamatinib —drug_protein→ EIF2AK2
    - `E343079` Fostamatinib —drug_protein→ MAP4K2
    - `rank:11BR060:drug:DRUGBANK:DB12010` model rank: Fostamatinib (#1 drug)
- ✅ supported — **EIF2AK2 (PKR)** – up‑regulated z=3.08
    - `pt:11BR060:protein_up:NCBIGene:5610` patient: EIF2AK2 protein up (z=3.1)
- ✅ supported — **Fostamatinib** – drug→EIF2AK2
    - `E343042` Fostamatinib —drug_protein→ EIF2AK2
- ✅ supported — **PNMT** – up‑regulated z=4.13
    - `pt:11BR060:protein_up:NCBIGene:5409` patient: PNMT protein up (z=4.1)
- ❌ removed — **Levmetamfetamine** – drug→PNMT
    - `E332326` CX717 —drug_protein→ GRIA1
- ✅ supported — **TP53** – somatic mutation p.T125T
    - `pt:11BR060:somatic_mutation:NCBIGene:7157` patient: TP53 p.T125T (somatic)
- ✅ supported — **Acetylsalicylic acid** – drug→TP53
    - `E337995` Acetylsalicylic acid —drug_protein→ TP53
- ✅ supported — **Zinc acetate** – drug→TP53
    - `E338000` Zinc acetate —drug_protein→ TP53
- ✅ supported — **RB1** – up‑regulated z=3.05
    - `pt:11BR060:protein_up:NCBIGene:5925` patient: RB1 protein up (z=3.1)
- ✅ supported — **Insulin human** – drug→RB1
    - `E336879` Insulin human —drug_protein→ RB1
- ✅ supported — **Model‑ranked kinase inhibitors** (tumor‑protein driven, not direct target matches): Ruxolitinib, Radotinib, Bosutinib, Dasatinib, Fasudil.
    - `rank:11BR060:drug:DRUGBANK:DB08877` model rank: Ruxolitinib (#3 drug)
    - `rank:11BR060:drug:DRUGBANK:DB12323` model rank: Radotinib (#4 drug)
    - `rank:11BR060:drug:DRUGBANK:DB06616` model rank: Bosutinib (#5 drug)
    - `rank:11BR060:drug:DRUGBANK:DB01254` model rank: Dasatinib (#9 drug)
    - `rank:11BR060:drug:DRUGBANK:DB08162` model rank: Fasudil (#10 drug)
- 🟡 hypothesis — Hypothesis: The co‑overexpression of ERBB2, GRB7, and LIMK2 creates a HER2‑driven, cytoskeleton‑remodeling state that is uniquely sensitive to combined HER2 blockade (e.g., pertuzumab + trastuzumab) plus LIMK2 inhibition (fostamatinib).
- ❌ removed — Compare to HER2+ models lacking LIMK2 overexpression.

## 11BR028

**Somatic mutations (3):** BCL11A p.D825N, NKX2-1 p.T203M, PTEN p.Q171E

**Verifier:** 17 supported, 1 hypothesis, 4 removed (of 22 claims); 6 caveat/experiment lines not scored.

### Answer

**Summary**
Patient 11BR028’s tumor shows three somatic mutations—PTEN p.Q171E, NKX2‑1 p.T203M, and BCL11A p.D825N—alongside a strong up‑regulation of proteins involved in MAPK scaffolding (SPAG9), ubiquitin/protein‑turnover (TRIM65, RNF135), DNA‑repair/replication (RECQL5, ZNF830, TOP2B), translation control (EIF2AK4, MIF4GD), and metabolic enzymes (ACOX1, GALK1, NME1) [pt:11BR028:somatic_mutation:NCBIGene:5728][pt:11BR028:somatic_mutation:NCBIGene:7080][pt:11BR028:somatic_mutation:NCBIGene:53335][pt:11BR028:protein_up:NCBIGene:9043][pt:11BR028:protein_up:NCBIGene:201292][pt:11BR028:protein_up:NCBIGene:84282][pt:11BR028:protein_up:NCBIGene:9400][pt:11BR028:protein_up:NCBIGene:91603][pt:11BR028:protein_up:NCBIGene:57409][pt:11BR028:protein_up:NCBIGene:51][pt:11BR028:protein_up:NCBIGene:2584][pt:11BR028:protein_up:NCBIGene:4830].

**Evidence paths**
- PTEN loss → PI3K‑AKT‑mTOR activation (canonical breast‑cancer mechanism) [E8271400][E8271401][E8271403]
- SPAG9 up‑regulated → binds JUN kinase & acts as MAP‑kinase scaffold → drives proliferation/survival signaling [pt:11BR028:protein_up:NCBIGene:9043][E3549394][E3549381]
- SPAG9 & ZC3H7A both interact with BIRC7 (survivin family), linking MAPK scaffolding to apoptosis inhibition [E113447][E242559]
- RECQL5 & ZNF830 up‑regulated → replication‑fork protection, DNA‑repair, mitotic checkpoint [pt:11BR028:protein_up:NCBIGene:9400][pt:11BR028:protein_up:NCBIGene:91603][E3732178][E3744750][E3779354][E3759007]
- TOP2B up‑regulated → topoisomerase II activity, sister‑chromatid segregation [pt:11BR028:protein_up:NCBIGene:7155][E3550859][E3776454]
- EIF2AK4 up‑regulated → GCN2‑mediated translational control, stress response [pt:11BR028:protein_up:NCBIGene:440275][E3773220][E3780765]
- NME1 up‑regulated → nucleoside‑diphosphate kinase, hypoxemia phenotype link [pt:11BR028:protein_up:NCBIGene:4830][E3062675]
- PRKCD up‑regulated (z=3.9) → DAG/IP3 & calmodulin signaling, calcium‑independent PKC activity [pt:11BR028:protein_up:NCBIGene:5580][E3815214][E3815211][E3549381]

**Mechanism**
Curated DisMech chains for breast carcinoma (MONDO:0004989) highlight: (1) ER/HER2 receptor heterogeneity [PMID:27349894]; (2) TP53 loss → EMT → organ tropism → immune evasion [PMID:23000897][PMID:21336307]; (3) PIK3CA mutations → constitutive PI3K‑AKT → mTOR activation [PMID:15647370]; (4) endocrine resistance; (5) angiogenic outgrowth; (6) cell survival/proliferation [E8137939][E8137942][E8137943][E8137935][E8137937][E8271400][E8271401][E8271403][E8271407][E8137940][E8271406].

**Targets / drugs**
- **Tamoxifen** – targets PRKCD (up‑regulated z=3.9) and has indication for female/invasive ductal breast carcinoma [E341709][pt:11BR028:protein_up:NCBIGene:5580][E363016][E389156]
- **Fostamatinib** – targets PRKCD (z=3.9) and EIF2AK4 (z=3.6) [E337572][pt:11BR028:protein_up:NCBIGene:5580][E343043][pt:11BR028:protein_up:NCBIGene:440275]
- **Dactinomycin / Daunorubicin / Etoposide** – target TOP2B (up‑regulated z=3.52) [E342098][pt:11BR028:protein_up:NCBIGene:7155][E337585][E337586]
- **Sofosbuvir / Adefovir dipivoxil / Tenofovir / Tenofovir alafenamide / Acyclovir / Decitabine / Lamivudine / Tenofovir disoproxil** – target NME1 (up‑regulated z=4.19) [E325423][pt:11BR028:protein_up:NCBIGene:4830][E325422][E325425][E325424][E327133][E327134][E325421][E327132]
- **Acyclovir** – also targets ADSS1 (up‑regulated z=3.47) [E327158][pt:11BR028:protein_up:NCBIGene:122622]
- **Phosphatidylethanolamine** – targets PTEN (mutated p.Q171E) [E342244][pt:11BR028:somatic_mutation:NCBIGene:5728]

*Model‑ranked (cohort‑relative) drug suggestions* – Ribavirin, Biotin, Adenosine phosphate, Iron, Ferrous gluconate, Inositol nicotinate, Minodronic acid, Nicotinamide, Serine, Artesunate, Cysteine, Riboflavin, Stanozolol, Ferrous fumarate, Ascorbic acid [rank:11BR028:drug:DRUGBANK:DB00811][rank:11BR028:drug:DRUGBANK:DB00121][rank:11BR028:drug:DRUGBANK:DB00131][rank:11BR028:drug:DRUGBANK:DB01592][rank:11BR028:drug:DRUGBANK:DB14488][rank:11BR028:drug:DRUGBANK:DB08949][rank:11BR028:drug:DRUGBANK:DB06548][rank:11BR028:drug:DRUGBANK:DB02701][rank:11BR028:drug:DRUGBANK:DB00133][rank:11BR028:drug:DRUGBANK:DB09274][rank:11BR028:drug:DRUGBANK:DB00151][rank:11BR028:drug:DRUGBANK:DB00140][rank:11BR028:drug:DRUGBANK:DB06718][rank:11BR028:drug:DRUGBANK:DB14491][rank:11BR028:drug:DRUGBANK:DB00126].

**Testable hypothesis**
Hypothesis: The co‑occurrence of PTEN loss, SPAG9‑driven MAPK scaffolding, and TOP2B/NME1‑mediated replication stress creates a vulnerability to combined PI3K‑AKT inhibition (e.g., alpelisib/capivasertib) and topoisomerase II poisoning (e.g., etoposide) or NME1‑targeted nucleoside analogs.
Experiment: Treat patient‑derived organoids or xenografts with alpelisib ± etoposide (or a NME1‑targeted nucleoside analog) and measure tumor growth, phospho‑AKT, γH2AX, and replication‑fork stability.

**Caveats**
- No GNN‑A risk estimate exists for BRCA; stage/grade/outcome cannot be inferred.
- Protein z‑scores are relative to the tumor cohort (no matched normal).
- Somatic mutations are tumor‐only; germline status unknown.
- Drug–target edges are PrimeKG links; shared targets are rationales to investigate, not proof of clinical benefit.
- Model‐ranked drugs are cohort‐relative scores, not validated predictions.

_Verifier: removed 4 claim(s) that had no supporting edge or PMID._

### Claims and what each citation is

- ✅ supported — Patient 11BR028’s tumor shows three somatic mutations—PTEN p.Q171E, NKX2‑1 p.T203M, and BCL11A p.D825N—alongside a strong up‑regulation of proteins involved in MAPK scaffolding (SPAG9), ubiquitin/protein‑turnover (TRIM65, RNF135), DNA‑repair/replication (RECQL5, ZNF830, TOP2B), translation control (EIF2AK4, MIF4GD), and metabolic enzymes (ACOX1, GALK1, NME1).
    - `pt:11BR028:somatic_mutation:NCBIGene:5728` patient: PTEN p.Q171E (somatic)
    - `pt:11BR028:somatic_mutation:NCBIGene:7080` patient: NKX2-1 p.T203M (somatic)
    - `pt:11BR028:somatic_mutation:NCBIGene:53335` patient: BCL11A p.D825N (somatic)
    - `pt:11BR028:protein_up:NCBIGene:9043` patient: SPAG9 protein up (z=5.8)
    - `pt:11BR028:protein_up:NCBIGene:201292` patient: TRIM65 protein up (z=5.7)
    - `pt:11BR028:protein_up:NCBIGene:84282` patient: RNF135 protein up (z=4.6)
    - `pt:11BR028:protein_up:NCBIGene:9400` patient: RECQL5 protein up (z=4.7)
    - `pt:11BR028:protein_up:NCBIGene:91603` patient: ZNF830 protein up (z=4.9)
    - `pt:11BR028:protein_up:NCBIGene:57409` patient: MIF4GD protein up (z=4.6)
    - `pt:11BR028:protein_up:NCBIGene:51` patient: ACOX1 protein up (z=4.5)
    - `pt:11BR028:protein_up:NCBIGene:2584` patient: GALK1 protein up (z=5.1)
    - `pt:11BR028:protein_up:NCBIGene:4830` patient: NME1 protein up (z=4.2)
- ❌ removed — The GNN‑A risk model is not available for BRCA, so no stage estimate is provided.
- ✅ supported — PTEN loss → PI3K‑AKT‑mTOR activation (canonical breast‑cancer mechanism)
    - `E8271400` breast carcinoma —dm_disease_has_basis_in→ PIK3CA Oncogenic Mutations
    - `E8271401` PIK3CA Oncogenic Mutations —dm_causes→ Constitutive PI3K-AKT Pathway Activation
    - `E8271403` Constitutive PI3K-AKT Pathway Activation —dm_causes→ mTOR Pathway Activation
- ✅ supported — SPAG9 up‑regulated → binds JUN kinase & acts as MAP‑kinase scaffold → drives proliferation/survival signaling
    - `pt:11BR028:protein_up:NCBIGene:9043` patient: SPAG9 protein up (z=5.8)
    - `E3549394` SPAG9 —molfunc_protein→ MAP-kinase scaffold activity
    - `E3549381` PRKCD —molfunc_protein→ calcium-independent protein kinase C activity
- ✅ supported — SPAG9 & ZC3H7A both interact with BIRC7 (survivin family), linking MAPK scaffolding to apoptosis inhibition
    - `E113447` SPAG9 —protein_protein→ BIRC7
    - `E242559` ZC3H7A —protein_protein→ BIRC7
- ✅ supported — RECQL5 & ZNF830 up‑regulated → replication‑fork protection, DNA‑repair, mitotic checkpoint
    - `pt:11BR028:protein_up:NCBIGene:9400` patient: RECQL5 protein up (z=4.7)
    - `pt:11BR028:protein_up:NCBIGene:91603` patient: ZNF830 protein up (z=4.9)
    - `E3732178` ZNF830 —bioprocess_protein→ replication fork protection
    - `E3744750` ZNF830 —bioprocess_protein→ mitotic DNA replication checkpoint signaling
    - `E3779354` ZNF830 —bioprocess_protein→ mitotic DNA damage checkpoint signaling
    - `E3759007` RECQL5 —bioprocess_protein→ replication-born double-strand break repair via sister chromatid exchange
- ✅ supported — TOP2B up‑regulated → topoisomerase II activity, sister‑chromatid segregation
    - `pt:11BR028:protein_up:NCBIGene:7155` patient: TOP2B protein up (z=3.5)
    - `E3550859` TOP2B —molfunc_protein→ DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
    - `E3776454` TOP2A —bioprocess_protein→ sister chromatid segregation
- ✅ supported — EIF2AK4 up‑regulated → GCN2‑mediated translational control, stress response
    - `pt:11BR028:protein_up:NCBIGene:440275` patient: EIF2AK4 protein up (z=3.6)
    - `E3773220` EIF2AK4 —bioprocess_protein→ regulation of translational initiation by eIF2 alpha phosphorylation
    - `E3780765` EIF2AK4 —bioprocess_protein→ GCN2-mediated signaling
- ✅ supported — NME1 up‑regulated → nucleoside‑diphosphate kinase, hypoxemia phenotype link
    - `pt:11BR028:protein_up:NCBIGene:4830` patient: NME1 protein up (z=4.2)
    - `E3062675` NME1 —phenotype_protein→ Hypoxemia
- ✅ supported — PRKCD up‑regulated (z=3.9) → DAG/IP3 & calmodulin signaling, calcium‑independent PKC activity
    - `pt:11BR028:protein_up:NCBIGene:5580` patient: PRKCD protein up (z=3.9)
    - `E3815214` PRKCD —pathway_protein→ DAG and IP3 signaling
    - `E3815211` PRKCD —pathway_protein→ Calmodulin induced events
    - `E3549381` PRKCD —molfunc_protein→ calcium-independent protein kinase C activity
- ✅ supported — Curated DisMech chains for breast carcinoma (MONDO:0004989) highlight: (1) ER/HER2 receptor heterogeneity; (2) TP53 loss → EMT → organ tropism → immune evasion; (3) PIK3CA mutations → constitutive PI3K‑AKT → mTOR activation; (4) endocrine resistance; (5) angiogenic outgrowth; (6) cell survival/proliferation.
    - `E8137939` breast carcinoma —dm_disease_has_basis_in→ ER and HER2 Receptor Heterogeneity
    - `E8137942` breast carcinoma —dm_disease_has_basis_in→ TP53 Loss of Function
    - `E8137943` TP53 Loss of Function —dm_causes→ EMT-Driven Dissemination
    - `E8137935` EMT-Driven Dissemination —dm_causes→ Organ-Specific Tropism
    - `E8137937` Organ-Specific Tropism —dm_causes→ Immune Evasion in Metastatic Niches
    - `E8271400` breast carcinoma —dm_disease_has_basis_in→ PIK3CA Oncogenic Mutations
    - `E8271401` PIK3CA Oncogenic Mutations —dm_causes→ Constitutive PI3K-AKT Pathway Activation
    - `E8271403` Constitutive PI3K-AKT Pathway Activation —dm_causes→ mTOR Pathway Activation
    - `E8271407` breast carcinoma —dm_disease_has_basis_in→ Endocrine Resistance
    - `E8137940` breast carcinoma —dm_disease_has_basis_in→ Angiogenic Outgrowth
    - `E8271406` breast carcinoma —dm_disease_has_basis_in→ Cell Survival and Proliferation
    - [PMID:27349894](https://pubmed.ncbi.nlm.nih.gov/27349894/)
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
    - [PMID:15647370](https://pubmed.ncbi.nlm.nih.gov/15647370/)
- ❌ removed — Approved/clinical drugs in these chains include palbociclib, fulvestrant, elacestrant, capivasertib, alpelisib, olaparib, talazoparib, trastuzumab deruxtecan, sacituzumab govitecan.
    - `E8137916` Palbociclib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137917` Fulvestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137919` Elacestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137921` capivasertib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137924` Olaparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137925` Talazoparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137927` Trastuzumab deruxtecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137929` Sacituzumab govitecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8271390` Alpelisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8271392` inavolisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - ⚠ cited edge doesn't name anything in the sentence: E8271392
- ❌ removed — Curated drug–target links with patient‐specific evidence*
- ✅ supported — **Tamoxifen** – targets PRKCD (up‑regulated z=3.9) and has indication for female/invasive ductal breast carcinoma
    - `E341709` Tamoxifen —drug_protein→ PRKCD
    - `pt:11BR028:protein_up:NCBIGene:5580` patient: PRKCD protein up (z=3.9)
    - `E363016` Tamoxifen —indication→ female breast carcinoma
    - `E389156` Tamoxifen —indication→ invasive ductal breast carcinoma
- ✅ supported — **Fostamatinib** – targets PRKCD (z=3.9) and EIF2AK4 (z=3.6)
    - `E337572` Fostamatinib —drug_protein→ PRKCD
    - `pt:11BR028:protein_up:NCBIGene:5580` patient: PRKCD protein up (z=3.9)
    - `E343043` Fostamatinib —drug_protein→ EIF2AK4
    - `pt:11BR028:protein_up:NCBIGene:440275` patient: EIF2AK4 protein up (z=3.6)
- ✅ supported — **Dactinomycin / Daunorubicin / Etoposide** – target TOP2B (up‑regulated z=3.52)
    - `E342098` Dactinomycin —drug_protein→ TOP2B
    - `pt:11BR028:protein_up:NCBIGene:7155` patient: TOP2B protein up (z=3.5)
    - `E337585` Daunorubicin —drug_protein→ TOP2B
    - `E337586` Etoposide —drug_protein→ TOP2B
- ✅ supported — **Sofosbuvir / Adefovir dipivoxil / Tenofovir / Tenofovir alafenamide / Acyclovir / Decitabine / Lamivudine / Tenofovir disoproxil** – target NME1 (up‑regulated z=4.19)
    - `E325423` Sofosbuvir —drug_protein→ NME1
    - `pt:11BR028:protein_up:NCBIGene:4830` patient: NME1 protein up (z=4.2)
    - `E325422` Adefovir dipivoxil —drug_protein→ NME1
    - `E325425` Tenofovir —drug_protein→ NME1
    - `E325424` Tenofovir alafenamide —drug_protein→ NME1
    - `E327133` Acyclovir —drug_protein→ NME1
    - `E327134` Decitabine —drug_protein→ NME1
    - `E325421` Lamivudine —drug_protein→ NME1
    - `E327132` Tenofovir disoproxil —drug_protein→ NME1
- ✅ supported — **Acyclovir** – also targets ADSS1 (up‑regulated z=3.47)
    - `E327158` Acyclovir —drug_protein→ ADSS1
    - `pt:11BR028:protein_up:NCBIGene:122622` patient: ADSS1 protein up (z=3.5)
- ✅ supported — **Phosphatidylethanolamine** – targets PTEN (mutated p.Q171E)
    - `E342244` Phosphatidylethanolamine —drug_protein→ PTEN
    - `pt:11BR028:somatic_mutation:NCBIGene:5728` patient: PTEN p.Q171E (somatic)
- ✅ supported — Model‑ranked (cohort‑relative) drug suggestions* – Ribavirin, Biotin, Adenosine phosphate, Iron, Ferrous gluconate, Inositol nicotinate, Minodronic acid, Nicotinamide, Serine, Artesunate, Cysteine, Riboflavin, Stanozolol, Ferrous fumarate, Ascorbic acid.
    - `rank:11BR028:drug:DRUGBANK:DB00811` model rank: Ribavirin (#1 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00121` model rank: Biotin (#2 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00131` model rank: Adenosine phosphate (#3 drug)
    - `rank:11BR028:drug:DRUGBANK:DB01592` model rank: Iron (#4 drug)
    - `rank:11BR028:drug:DRUGBANK:DB14488` model rank: Ferrous gluconate (#5 drug)
    - `rank:11BR028:drug:DRUGBANK:DB08949` model rank: Inositol nicotinate (#6 drug)
    - `rank:11BR028:drug:DRUGBANK:DB06548` model rank: Minodronic acid (#7 drug)
    - `rank:11BR028:drug:DRUGBANK:DB02701` model rank: Nicotinamide (#8 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00133` model rank: Serine (#9 drug)
    - `rank:11BR028:drug:DRUGBANK:DB09274` model rank: Artesunate (#10 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00151` model rank: Cysteine (#11 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00140` model rank: Riboflavin (#12 drug)
    - `rank:11BR028:drug:DRUGBANK:DB06718` model rank: Stanozolol (#13 drug)
    - `rank:11BR028:drug:DRUGBANK:DB14491` model rank: Ferrous fumarate (#14 drug)
    - `rank:11BR028:drug:DRUGBANK:DB00126` model rank: Ascorbic acid (#15 drug)
- ❌ removed — These are model suggestions only, not evidence of efficacy.
- 🟡 hypothesis — Hypothesis: The co‑occurrence of PTEN loss, SPAG9‑driven MAPK scaffolding, and TOP2B/NME1‑mediated replication stress creates a vulnerability to combined PI3K‑AKT inhibition (e.g., alpelisib/capivasertib) and topoisomerase II poisoning (e.g., etoposide) or NME1‑targeted nucleoside analogs.

## 18BR019

**Somatic mutations (1):** DNMT3A

**Verifier:** 19 supported, 1 hypothesis, 4 removed (of 24 claims); 7 caveat/experiment lines not scored.

### Answer

**Evidence paths**
- Somatic *DNMT3A* mutation → epigenetic dysregulation [pt:18BR019:somatic_mutation:NCBIGene:1788]
- NCAM1↑ (z=4.78) & HAPLN1↑ (z=4.50) → collagen-containing ECM [E3558355, E3558251]
- EPHB2↑ (z=2.64) → neuron projection & negative NMDA regulation [E3590797, E3757800]
- MAPK11↑ (z=2.80) → p38MAPK & AP-1 activation pathways [E3815589, E3815596]
- PCSK1↑ (z=3.04) → prohormone processing (IAPP, REN) [E40432, E180099]
- CPB1↑ (z=3.14) → angiotensinogen→angiotensin metabolism [E3796329]
- GPD2↑ (z=3.23) → mitochondrial glycerol-3-P shuttle [E3597217, E3762497]
- QDPR↑ (z=3.14) → dihydrobiopterin metabolism & neuron projection [E3773582, E3590889]
- Decitabine → DNMT3A (mutated) [E343403] + [pt:18BR019:somatic_mutation:NCBIGene:1788]
- Regorafenib/Minocycline → MAPK11 (up) [E338054, E343381] + [pt:18BR019:protein_up:NCBIGene:5600]
- Fostamatinib → EPHB2 (up) [E339807] + [pt:18BR019:protein_up:NCBIGene:2048]
- Insulin human → PCSK1 (up) [E322549] + [pt:18BR019:protein_up:NCBIGene:5122]

**Mechanism**
Breast carcinoma mechanisms in the graph: ER/HER2 heterogeneity [PMID:27349894]; TP53 loss → EMT → organ tropism → immune evasion [PMID:23000897, PMID:21336307]; PIK3CA mutation → PI3K-AKT → mTOR activation [PMID:15647370]; endocrine resistance; angiogenic outgrowth; cell survival/proliferation.

**Targets / drugs**
1. **DNMT3A** (mutated) – decitabine (hypomethylating agent) [E343403]; procaine (no cancer indication) [E343402]
2. **MAPK11/p38** (up) – regorafenib (multi-kinase inhibitor) [E338054]; minocycline (tetracycline) [E343381]
3. **EPHB2** (up) – fostamatinib (SYK inhibitor, EphB2 off-target) [E339807]
4. **PCSK1** (up) – insulin human (substrate/enzyme relationship) [E322549]
5. **CPB1** (up) – citric acid (metal chelator) [E337896]
6. **Model-ranked** (cohort-relative GNN scores): cannabidiol [rank:18BR019:drug:DRUGBANK:DB09061], nalmefene [rank:18BR019:drug:DRUGBANK:DB06230], niacin [rank:18BR019:drug:DRUGBANK:DB00627], buformin [rank:18BR019:drug:DRUGBANK:DB04830], stiripentol [rank:18BR019:drug:DRUGBANK:DB09118], gilteritinib [rank:18BR019:drug:DRUGBANK:DB12141]

**Testable hypothesis**
Hypothesis: The *DNMT3A* mutation cooperates with NCAM1/HAPLN1-driven ECM remodeling and MAPK11-mediated stress signaling to promote an invasive, neural-like phenotype. Experiment: Treat *DNMT3A*-mutant/NCAM1-high breast cancer organoids with decitabine ± regorafenib; measure invasion, p38 phosphorylation, and ECM gene signatures.

**Caveats**
- No GNN-A risk estimate for BRCA; tumor drivers are proteomic/mutational correlations, not causal proof.
- Protein z-scores are cohort-relative (no matched normal); “up” may reflect shared tumor programs.
- Drug–target edges are PrimeKG links; shared target ≠ clinical efficacy. Model-ranked drugs are hypothesis-generating only.
- No phenotypes or medications recorded; clinical_drivers absent.
- Germline status of *DNMT3A* unknown; somatic call only.

_Verifier: removed 4 claim(s) that had no supporting edge or PMID._

### Claims and what each citation is

- ❌ removed — Patient 18BR019’s tumor shows a somatic *DNMT3A* mutation and a striking up-regulation of neural/ECM adhesion proteins (NCAM1, HAPLN1, MAGI2, PODXL, EPHB2), mitochondrial metabolic enzymes (GPD2, QDPR, STEAP4, ATP7B), and stress-response kinases (MAPK11/p38).
- ❌ removed — The GNN-A risk model is unavailable for BRCA, so the tumor drivers are inferred from the proteomic and mutational profile.
- ❌ removed — Model-ranked drugs highlight cannabidiol and nalmefene, while curated drug–target links point to decitabine (DNMT3A), regorafenib/minocycline (MAPK11), fostamatinib (EPHB2), and insulin (PCSK1) as rationally matched agents.
- ✅ supported — Somatic *DNMT3A* mutation → epigenetic dysregulation
    - `pt:18BR019:somatic_mutation:NCBIGene:1788` patient: DNMT3A (somatic)
- ✅ supported — NCAM1↑ (z=4.78) & HAPLN1↑ (z=4.50) → collagen-containing ECM
    - `E3558355` NCAM1 —cellcomp_protein→ collagen-containing extracellular matrix
    - `E3558251` HAPLN1 —cellcomp_protein→ collagen-containing extracellular matrix
- ✅ supported — EPHB2↑ (z=2.64) → neuron projection & negative NMDA regulation
    - `E3590797` EPHB2 —cellcomp_protein→ neuron projection
    - `E3757800` EPHB2 —bioprocess_protein→ negative regulation of NMDA glutamate receptor activity
- ✅ supported — MAPK11↑ (z=2.80) → p38MAPK & AP-1 activation pathways
    - `E3815589` MAPK11 —pathway_protein→ p38MAPK events
    - `E3815596` MAPK11 —pathway_protein→ Activation of the AP-1 family of transcription factors
- ✅ supported — PCSK1↑ (z=3.04) → prohormone processing (IAPP, REN)
    - `E40432` IAPP —protein_protein→ PCSK1
    - `E180099` PCSK1 —protein_protein→ REN
- ✅ supported — CPB1↑ (z=3.14) → angiotensinogen→angiotensin metabolism
    - `E3796329` CPB1 —pathway_protein→ Metabolism of Angiotensinogen to Angiotensins
- ✅ supported — GPD2↑ (z=3.23) → mitochondrial glycerol-3-P shuttle
    - `E3597217` GPD2 —cellcomp_protein→ mitochondrial inner membrane
    - `E3762497` GPD2 —bioprocess_protein→ glycerophosphate shuttle
- ✅ supported — QDPR↑ (z=3.14) → dihydrobiopterin metabolism & neuron projection
    - `E3773582` QDPR —bioprocess_protein→ dihydrobiopterin metabolic process
    - `E3590889` QDPR —cellcomp_protein→ neuron projection
- ✅ supported — Decitabine → DNMT3A (mutated) +
    - `E343403` Decitabine —drug_protein→ DNMT3A
    - `pt:18BR019:somatic_mutation:NCBIGene:1788` patient: DNMT3A (somatic)
- ✅ supported — Regorafenib/Minocycline → MAPK11 (up) +
    - `E338054` Regorafenib —drug_protein→ MAPK11
    - `E343381` Minocycline —drug_protein→ MAPK11
    - `pt:18BR019:protein_up:NCBIGene:5600` patient: MAPK11 protein up (z=2.8)
- ✅ supported — Fostamatinib → EPHB2 (up) +
    - `E339807` Fostamatinib —drug_protein→ EPHB2
    - `pt:18BR019:protein_up:NCBIGene:2048` patient: EPHB2 protein up (z=2.6)
- ✅ supported — Insulin human → PCSK1 (up) +
    - `E322549` Insulin human —drug_protein→ PCSK1
    - `pt:18BR019:protein_up:NCBIGene:5122` patient: PCSK1 protein up (z=3.0)
- ✅ supported — Breast carcinoma mechanisms in the graph: ER/HER2 heterogeneity; TP53 loss → EMT → organ tropism → immune evasion; PIK3CA mutation → PI3K-AKT → mTOR activation; endocrine resistance; angiogenic outgrowth; cell survival/proliferation.
    - [PMID:27349894](https://pubmed.ncbi.nlm.nih.gov/27349894/)
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
    - [PMID:15647370](https://pubmed.ncbi.nlm.nih.gov/15647370/)
- ❌ removed — Approved/clinical drugs with DisMech edges: palbociclib, fulvestrant, elacestrant, capivasertib, olaparib, talazoparib, trastuzumab deruxtecan, sacituzumab govitecan, alpelisib, inavolisib.
- ✅ supported — **DNMT3A** (mutated) – decitabine (hypomethylating agent); procaine (no cancer indication)
    - `E343403` Decitabine —drug_protein→ DNMT3A
    - `E343402` Procaine —drug_protein→ DNMT3A
- ✅ supported — **MAPK11/p38** (up) – regorafenib (multi-kinase inhibitor); minocycline (tetracycline)
    - `E338054` Regorafenib —drug_protein→ MAPK11
    - `E343381` Minocycline —drug_protein→ MAPK11
- ✅ supported — **EPHB2** (up) – fostamatinib (SYK inhibitor, EphB2 off-target)
    - `E339807` Fostamatinib —drug_protein→ EPHB2
- ✅ supported — **PCSK1** (up) – insulin human (substrate/enzyme relationship)
    - `E322549` Insulin human —drug_protein→ PCSK1
- ✅ supported — **CPB1** (up) – citric acid (metal chelator)
    - `E337896` Citric acid —drug_protein→ CPB1
- ✅ supported — **Model-ranked** (cohort-relative GNN scores): cannabidiol, nalmefene, niacin, buformin, stiripentol, gilteritinib
    - `rank:18BR019:drug:DRUGBANK:DB09061` model rank: Cannabidiol (#1 drug)
    - `rank:18BR019:drug:DRUGBANK:DB06230` model rank: Nalmefene (#2 drug)
    - `rank:18BR019:drug:DRUGBANK:DB00627` model rank: Niacin (#3 drug)
    - `rank:18BR019:drug:DRUGBANK:DB04830` model rank: Buformin (#4 drug)
    - `rank:18BR019:drug:DRUGBANK:DB09118` model rank: Stiripentol (#5 drug)
    - `rank:18BR019:drug:DRUGBANK:DB12141` model rank: Gilteritinib (#6 drug)
- 🟡 hypothesis — Hypothesis: The *DNMT3A* mutation cooperates with NCAM1/HAPLN1-driven ECM remodeling and MAPK11-mediated stress signaling to promote an invasive, neural-like phenotype.

## 18BR003

**Somatic mutations (34):** ALK p.G747R, ARHGEF12 p.E424Q, ARID1A p.S637C;p.S1611*, ATM p.E1199Q, BRCA2 p.D1337H;p.Q1562*;p.E1593Q;p.D2592N, CBL p.P494S, CDH1 p.S9*, COL1A1 p.R253Q, DNM2 p.F258L, FEV p.E55Q, GATA3 p.M293K, IL7R p.S39*, JUN p.E112K, KDM5C p.M571I, KMT2C p.L955F;p.H367Y, LIFR p.S616L, LPP p.E529D, MAP3K1 p.P666S, MLLT10 p.E146K, MLLT6 p.E365Q, MSH2 p.S743L, NSD1 p.E808K;p.E844Q, NUMA1, PAX3 p.S208F, PDE4DIP p.P993S, PDGFRA p.L655F, PICALM p.G419E, PIK3CA p.E453K;p.E545K, PMS1 p.Q16*, RBM15 p.M45I, REL p.S479L, SUFU p.Q332H, USP6 p.L1243F, ZNF521 p.E1000K

**Verifier:** 19 supported, 1 hypothesis, 2 removed (of 22 claims); 8 caveat/experiment lines not scored.

### Answer

**Summary**
Patient 18BR003’s tumor is driven by co-occurring oncogenic mutations in *PIK3CA* (p.E453K;p.E545K), *ALK* (p.G747R), *PDGFRA* (p.L655F), *JUN* (p.E112K) and *BRCA2* (multiple truncating/ missense changes), together with loss of *CDH1* (mutation + protein down‑regulation) and broad down‑regulation of catenin/cadherin complex members (*CTNNB1*, *JUP*, *CTNNA1*) [pt:18BR003:somatic_mutation:NCBIGene:5290][pt:18BR003:somatic_mutation:NCBIGene:238][pt:18BR003:somatic_mutation:NCBIGene:5156][pt:18BR003:somatic_mutation:NCBIGene:3725][pt:18BR003:somatic_mutation:NCBIGene:675][pt:18BR003:somatic_mutation:NCBIGene:999][pt:18BR003:protein_down:NCBIGene:999][pt:18BR003:protein_down:NCBIGene:1499][pt:18BR003:protein_down:NCBIGene:3728][pt:18BR003:protein_down:NCBIGene:1495]. The most up‑regulated tumor proteins include *MTRR*, *PANK4*, *GRB2*, *TNIK*, *EZR*, *SOCS6* and *PDE5A* [pt:18BR003:protein_up:NCBIGene:4552][pt:18BR003:protein_up:NCBIGene:55229][pt:18BR003:protein_up:NCBIGene:2885][pt:18BR003:protein_up:NCBIGene:23043][pt:18BR003:protein_up:NCBIGene:7430][pt:18BR003:protein_up:NCBIGene:9306][pt:18BR003:protein_up:NCBIGene:8654].

**Evidence paths**
- *PIK3CA* mutation → protein‑protein interaction with *IRS4* and *ADAP1* → *IRS4* binds *SOCS6* (up‑regulated) [E195867][E136264][E186521][pt:18BR003:protein_up:NCBIGene:9306]
- *ALK* mutation → protein‑protein interaction with *IRS4* and *SRCIN1* [E210894][E183975]
- *GRB2* (up‑regulated) → protein‑protein interactions with *IRS4*, *NKD2*, *PDE6G*, *TXK*; *TXK* binds *SOCS6* [E111334][E102110][E104027][E120283][E197442]
- *GRB2* participates in PDGFRA mutant signaling pathways [E3804107][E3804108]
- *PDE5A* (up‑regulated) interacts with *PDE6G* [E169495]
- *CDH1* mutation + down‑regulation alongside *CTNNB1*, *JUP*, *CTNNA1* down‑regulation indicates cadherin/catenin complex disruption [pt:18BR003:somatic_mutation:NCBIGene:999][pt:18BR003:protein_down:NCBIGene:999][pt:18BR003:protein_down:NCBIGene:1499][pt:18BR003:protein_down:NCBIGene:3728][pt:18BR003:protein_down:NCBIGene:1495]

**Mechanism**
Curated breast carcinoma mechanisms show: (1) *PIK3CA* oncogenic mutations drive constitutive PI3K‑AKT pathway activation and mTOR signaling [PMID:15647370][E8271400][E8271401][E8271403]; (2) *TP53* loss (not mutated here) enables EMT, organ‑specific tropism and immune evasion [PMID:23000897][PMID:21336307][E8137942][E8137943][E8137935][E8137937]; (3) ER/HER2 receptor heterogeneity shapes disease subtypes [PMID:27349894][E8137939]. Approved/clinical drugs for breast carcinoma include alpelisib (PI3Kα inhibitor) [E8271390][PMID:37743730], PARP inhibitors (olaparib, talazoparib) [E8137924][E8137925], CDK4/6 inhibitors (palbociclib) [E8137916], SERDs (fulvestrant, elacestrant) [E8137917][E8137919], AKT inhibitor (capivasertib) [E8137921], and ADCs (trastuzumab deruxtecan, sacituzumab govitecan) [E8137927][E8137929].

**Targets / drugs** (ranked by combined mechanistic and model evidence)
1. **PIK3CA** – *Alpelisib* (approved for *PIK3CA*‑mutant HR+/HER2− breast cancer) targets the patient’s *PIK3CA* p.E453K;p.E545K mutation [E337469][pt:18BR003:somatic_mutation:NCBIGene:5290][E8271390]. *Copanlisib* also targets *PIK3CA* [E337470][pt:18BR003:somatic_mutation:NCBIGene:5290].
2. **ALK** – *Lorlatinib* (model‑ranked #5 [rank:18BR003:drug:DRUGBANK:DB12130]) and *Alectinib*, *Ceritinib*, *Crizotinib* target the *ALK* p.G747R mutation [E330183][E330181][E330180][E330179][pt:18BR003:somatic_mutation:NCBIGene:238].
3. **PDGFRA** – *Olaratumab* targets the *PDGFRA* p.L655F mutation [E334052][pt:18BR003:somatic_mutation:NCBIGene:5156]; other TKIs (e.g., *Amuvatinib*, *Becaplermin*) share this target [E334062][E334048][pt:18BR003:somatic_mutation:NCBIGene:5156].
4. **JUN** – *Vinblastine* (has breast cancer indication [E362948]) and *Irbesartan* target the *JUN* p.E112K mutation [E335171][E335172][pt:18BR003:somatic_mutation:NCBIGene:3725].
5. **GRB2** – *Pegademase* targets up‑regulated *GRB2* (z=3.27) and is model‑ranked #8 [E334429][pt:18BR003:protein_up:NCBIGene:2885][rank:18BR003:drug:DRUGBANK:DB00061].
6. **PDE5A** – *Avanafil*, *Udenafil* target up‑regulated *PDE5A* (z=2.61) [E328854][E328856][pt:18BR003:protein_up:NCBIGene:8654].
7. **BRCA2** – PARP inhibitors (*Olaparib*, *Talazoparib*) are indicated in BRCA‑mutant breast cancer [E8137924][E8137925]; the patient carries multiple *BRCA2* somatic mutations [pt:18BR003:somatic_mutation:NCBIGene:675].
8. **Model‑ranked only** (no direct target link in graph): *Norepinephrine*, *Podofilox*, *Asparaginase*, *Dopamine*, *Brentuximab vedotin*, *Romidepsin*, *Vorinostat*, *Ecabet* [rank:18BR003:drug:DRUGBANK:DB00368][rank:18BR003:drug:DRUGBANK:DB01179][rank:18BR003:drug:DRUGBANK:DB00023][rank:18BR003:drug:DRUGBANK:DB00988][rank:18BR003:drug:DRUGBANK:DB08870][rank:18BR003:drug:DRUGBANK:DB06176][rank:18BR003:drug:DRUGBANK:DB02546][rank:18BR003:drug:DRUGBANK:DB05265].

**Testable hypothesis**
Hypothesis: The co‑occurrence of *PIK3CA* and *ALK* activating mutations with *BRCA2* loss creates a tumor dependent on both PI3K‑AKT‑mTOR and ALK signaling, while homologous recombination deficiency sensitizes to PARP inhibition. Experiment: Treat patient‑derived organoids or xenografts with alpelisib + lorlatinib ± olaparib; measure viability, p‑AKT, p‑ALK, and γH2AX foci.

**Caveats**
- All mutations are somatic tumor calls; germline status is unknown.
- Protein z‑scores are relative to the tumor cohort (no matched normal).
- GNN‑A risk model is unavailable for BRCA; no stage/prognosis estimate.
- Drug–target edges are from PrimeKG; indication edges may reflect trials, not approvals. Shared targets are rationales to investigate, not evidence of efficacy.
- Model‑ranked drugs/genes reflect cohort‑relative scoring on tumor proteins; they do not incorporate clinical phenotypes (none recorded).
- Subgraph is limited to 195 nodes; additional interactions may exist.

_Verifier: removed 2 claim(s) that had no supporting edge or PMID._

### Claims and what each citation is

- ✅ supported — Patient 18BR003’s tumor is driven by co-occurring oncogenic mutations in *PIK3CA* (p.E453K;p.E545K), *ALK* (p.G747R), *PDGFRA* (p.L655F), *JUN* (p.E112K) and *BRCA2* (multiple truncating/ missense changes), together with loss of *CDH1* (mutation + protein down‑regulation) and broad down‑regulation of catenin/cadherin complex members (*CTNNB1*, *JUP*, *CTNNA1*).
    - `pt:18BR003:somatic_mutation:NCBIGene:5290` patient: PIK3CA p.E453K;p.E545K (somatic)
    - `pt:18BR003:somatic_mutation:NCBIGene:238` patient: ALK p.G747R (somatic)
    - `pt:18BR003:somatic_mutation:NCBIGene:5156` patient: PDGFRA p.L655F (somatic)
    - `pt:18BR003:somatic_mutation:NCBIGene:3725` patient: JUN p.E112K (somatic)
    - `pt:18BR003:somatic_mutation:NCBIGene:675` patient: BRCA2 p.D1337H;p.Q1562*;p.E1593Q;p.D2592N (somatic)
    - `pt:18BR003:somatic_mutation:NCBIGene:999` patient: CDH1 p.S9* (somatic)
    - `pt:18BR003:protein_down:NCBIGene:999` patient: CDH1 protein down (z=-2.8)
    - `pt:18BR003:protein_down:NCBIGene:1499` patient: CTNNB1 protein down (z=-2.9)
    - `pt:18BR003:protein_down:NCBIGene:3728` patient: JUP protein down (z=-3.0)
    - `pt:18BR003:protein_down:NCBIGene:1495` patient: CTNNA1 protein down (z=-3.3)
- ✅ supported — The most up‑regulated tumor proteins include *MTRR*, *PANK4*, *GRB2*, *TNIK*, *EZR*, *SOCS6* and *PDE5A*.
    - `pt:18BR003:protein_up:NCBIGene:4552` patient: MTRR protein up (z=4.6)
    - `pt:18BR003:protein_up:NCBIGene:55229` patient: PANK4 protein up (z=3.8)
    - `pt:18BR003:protein_up:NCBIGene:2885` patient: GRB2 protein up (z=3.3)
    - `pt:18BR003:protein_up:NCBIGene:23043` patient: TNIK protein up (z=3.1)
    - `pt:18BR003:protein_up:NCBIGene:7430` patient: EZR protein up (z=2.7)
    - `pt:18BR003:protein_up:NCBIGene:9306` patient: SOCS6 protein up (z=2.6)
    - `pt:18BR003:protein_up:NCBIGene:8654` patient: PDE5A protein up (z=2.6)
- ❌ removed — The GNN‑A risk model is not available for BRCA, so no stage‑risk estimate is provided.
- ✅ supported — *PIK3CA* mutation → protein‑protein interaction with *IRS4* and *ADAP1* → *IRS4* binds *SOCS6* (up‑regulated)
    - `E195867` PIK3CA —protein_protein→ IRS4
    - `E136264` PIK3CA —protein_protein→ ADAP1
    - `E186521` IRS4 —protein_protein→ SOCS6
    - `pt:18BR003:protein_up:NCBIGene:9306` patient: SOCS6 protein up (z=2.6)
- ✅ supported — *ALK* mutation → protein‑protein interaction with *IRS4* and *SRCIN1*
    - `E210894` ALK —protein_protein→ IRS4
    - `E183975` ALK —protein_protein→ SRCIN1
- ✅ supported — *GRB2* (up‑regulated) → protein‑protein interactions with *IRS4*, *NKD2*, *PDE6G*, *TXK*; *TXK* binds *SOCS6*
    - `E111334` GRB2 —protein_protein→ IRS4
    - `E102110` GRB2 —protein_protein→ NKD2
    - `E104027` GRB2 —protein_protein→ PDE6G
    - `E120283` GRB2 —protein_protein→ TXK
    - `E197442` TXK —protein_protein→ SOCS6
- ✅ supported — *GRB2* participates in PDGFRA mutant signaling pathways
    - `E3804107` GRB2 —pathway_protein→ Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
    - `E3804108` GRB2 —pathway_protein→ Signaling by PDGFRA extracellular domain mutants
- ✅ supported — *PDE5A* (up‑regulated) interacts with *PDE6G*
    - `E169495` PDE6G —protein_protein→ PDE5A
- ✅ supported — *CDH1* mutation + down‑regulation alongside *CTNNB1*, *JUP*, *CTNNA1* down‑regulation indicates cadherin/catenin complex disruption
    - `pt:18BR003:somatic_mutation:NCBIGene:999` patient: CDH1 p.S9* (somatic)
    - `pt:18BR003:protein_down:NCBIGene:999` patient: CDH1 protein down (z=-2.8)
    - `pt:18BR003:protein_down:NCBIGene:1499` patient: CTNNB1 protein down (z=-2.9)
    - `pt:18BR003:protein_down:NCBIGene:3728` patient: JUP protein down (z=-3.0)
    - `pt:18BR003:protein_down:NCBIGene:1495` patient: CTNNA1 protein down (z=-3.3)
- ✅ supported — Curated breast carcinoma mechanisms show: (1) *PIK3CA* oncogenic mutations drive constitutive PI3K‑AKT pathway activation and mTOR signaling; (2) *TP53* loss (not mutated here) enables EMT, organ‑specific tropism and immune evasion; (3) ER/HER2 receptor heterogeneity shapes disease subtypes.
    - `E8271400` breast carcinoma —dm_disease_has_basis_in→ PIK3CA Oncogenic Mutations
    - `E8271401` PIK3CA Oncogenic Mutations —dm_causes→ Constitutive PI3K-AKT Pathway Activation
    - `E8271403` Constitutive PI3K-AKT Pathway Activation —dm_causes→ mTOR Pathway Activation
    - `E8137942` breast carcinoma —dm_disease_has_basis_in→ TP53 Loss of Function
    - `E8137943` TP53 Loss of Function —dm_causes→ EMT-Driven Dissemination
    - `E8137935` EMT-Driven Dissemination —dm_causes→ Organ-Specific Tropism
    - `E8137937` Organ-Specific Tropism —dm_causes→ Immune Evasion in Metastatic Niches
    - `E8137939` breast carcinoma —dm_disease_has_basis_in→ ER and HER2 Receptor Heterogeneity
    - [PMID:15647370](https://pubmed.ncbi.nlm.nih.gov/15647370/)
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
    - [PMID:27349894](https://pubmed.ncbi.nlm.nih.gov/27349894/)
- ✅ supported — Approved/clinical drugs for breast carcinoma include alpelisib (PI3Kα inhibitor), PARP inhibitors (olaparib, talazoparib), CDK4/6 inhibitors (palbociclib), SERDs (fulvestrant, elacestrant), AKT inhibitor (capivasertib), and ADCs (trastuzumab deruxtecan, sacituzumab govitecan).
    - `E8271390` Alpelisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137924` Olaparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137925` Talazoparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137916` Palbociclib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137917` Fulvestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137919` Elacestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137921` capivasertib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137927` Trastuzumab deruxtecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137929` Sacituzumab govitecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - [PMID:37743730](https://pubmed.ncbi.nlm.nih.gov/37743730/)
- ✅ supported — **PIK3CA** – *Alpelisib* (approved for *PIK3CA*‑mutant HR+/HER2− breast cancer) targets the patient’s *PIK3CA* p.E453K;p.E545K mutation.
    - `E337469` Alpelisib —drug_protein→ PIK3CA
    - `pt:18BR003:somatic_mutation:NCBIGene:5290` patient: PIK3CA p.E453K;p.E545K (somatic)
    - `E8271390` Alpelisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
- ✅ supported — *Copanlisib* also targets *PIK3CA*.
    - `E337470` Copanlisib —drug_protein→ PIK3CA
    - `pt:18BR003:somatic_mutation:NCBIGene:5290` patient: PIK3CA p.E453K;p.E545K (somatic)
- ✅ supported — **ALK** – *Lorlatinib* (model‑ranked #5 ) and *Alectinib*, *Ceritinib*, *Crizotinib* target the *ALK* p.G747R mutation.
    - `rank:18BR003:drug:DRUGBANK:DB12130` model rank: Lorlatinib (#5 drug)
    - `E330183` Lorlatinib —drug_protein→ ALK
    - `E330181` Alectinib —drug_protein→ ALK
    - `E330180` Ceritinib —drug_protein→ ALK
    - `E330179` Crizotinib —drug_protein→ ALK
    - `pt:18BR003:somatic_mutation:NCBIGene:238` patient: ALK p.G747R (somatic)
- ✅ supported — **PDGFRA** – *Olaratumab* targets the *PDGFRA* p.L655F mutation; other TKIs (e.g., *Amuvatinib*, *Becaplermin*) share this target.
    - `E334052` Olaratumab —drug_protein→ PDGFRA
    - `pt:18BR003:somatic_mutation:NCBIGene:5156` patient: PDGFRA p.L655F (somatic)
    - `E334062` Amuvatinib —drug_protein→ PDGFRA
    - `E334048` Becaplermin —drug_protein→ PDGFRA
- ✅ supported — **JUN** – *Vinblastine* (has breast cancer indication ) and *Irbesartan* target the *JUN* p.E112K mutation.
    - `E362948` Vinblastine —indication→ female breast carcinoma
    - `E335171` Vinblastine —drug_protein→ JUN
    - `E335172` Irbesartan —drug_protein→ JUN
    - `pt:18BR003:somatic_mutation:NCBIGene:3725` patient: JUN p.E112K (somatic)
- ✅ supported — **GRB2** – *Pegademase* targets up‑regulated *GRB2* (z=3.27) and is model‑ranked #8.
    - `E334429` Pegademase —drug_protein→ GRB2
    - `pt:18BR003:protein_up:NCBIGene:2885` patient: GRB2 protein up (z=3.3)
    - `rank:18BR003:drug:DRUGBANK:DB00061` model rank: Pegademase (#8 drug)
- ✅ supported — **PDE5A** – *Avanafil*, *Udenafil* target up‑regulated *PDE5A* (z=2.61).
    - `E328854` Avanafil —drug_protein→ PDE5A
    - `E328856` Udenafil —drug_protein→ PDE5A
    - `pt:18BR003:protein_up:NCBIGene:8654` patient: PDE5A protein up (z=2.6)
- ✅ supported — **BRCA2** – PARP inhibitors (*Olaparib*, *Talazoparib*) are indicated in BRCA‑mutant breast cancer; the patient carries multiple *BRCA2* somatic mutations.
    - `E8137924` Olaparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137925` Talazoparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `pt:18BR003:somatic_mutation:NCBIGene:675` patient: BRCA2 p.D1337H;p.Q1562*;p.E1593Q;p.D2592N (somatic)
- ✅ supported — **Model‑ranked only** (no direct target link in graph): *Norepinephrine*, *Podofilox*, *Asparaginase*, *Dopamine*, *Brentuximab vedotin*, *Romidepsin*, *Vorinostat*, *Ecabet*.
    - `rank:18BR003:drug:DRUGBANK:DB00368` model rank: Norepinephrine (#1 drug)
    - `rank:18BR003:drug:DRUGBANK:DB01179` model rank: Podofilox (#2 drug)
    - `rank:18BR003:drug:DRUGBANK:DB00023` model rank: Asparaginase Escherichia coli (#3 drug)
    - `rank:18BR003:drug:DRUGBANK:DB00988` model rank: Dopamine (#4 drug)
    - `rank:18BR003:drug:DRUGBANK:DB08870` model rank: Brentuximab vedotin (#6 drug)
    - `rank:18BR003:drug:DRUGBANK:DB06176` model rank: Romidepsin (#7 drug)
    - `rank:18BR003:drug:DRUGBANK:DB02546` model rank: Vorinostat (#9 drug)
    - `rank:18BR003:drug:DRUGBANK:DB05265` model rank: Ecabet (#10 drug)
- 🟡 hypothesis — Hypothesis: The co‑occurrence of *PIK3CA* and *ALK* activating mutations with *BRCA2* loss creates a tumor dependent on both PI3K‑AKT‑mTOR and ALK signaling, while homologous recombination deficiency sensitizes to PARP inhibition.
- ❌ removed — Compare to single agents and to models with only one of these alterations.

## 05BR044

**Somatic mutations (4):** AKT1 p.E17K, CD74 p.Q13R, RET p.G453R, TP53 p.R337C

**Verifier:** 22 supported, 1 hypothesis, 1 removed (of 24 claims); 6 caveat/experiment lines not scored.

### Answer

**Summary**
Patient 05BR044’s tumor carries somatic mutations in *AKT1* (p.E17K), *RET* (p.G453R), *TP53* (p.R337C) and *CD74* (p.Q13R) [pt:05BR044:somatic_mutation:NCBIGene:207][pt:05BR044:somatic_mutation:NCBIGene:5979][pt:05BR044:somatic_mutation:NCBIGene:7157][pt:05BR044:somatic_mutation:NCBIGene:972]. The most up‑regulated tumor proteins are SCP2, P4HB, MCCC1, GOT1 and ACSL3 [pt:05BR044:protein_up:NCBIGene:6342][pt:05BR044:protein_up:NCBIGene:5034][pt:05BR044:protein_up:NCBIGene:56922][pt:05BR044:protein_up:NCBIGene:2805][pt:05BR044:protein_up:NCBIGene:2181].  Model‑ranked genes highlight lipid‑metabolism and detoxification enzymes (UGT1A6, EBPL, FADS2, MBOAT7) [rank:05BR044:gene:NCBIGene:54578][rank:05BR044:gene:NCBIGene:84650][rank:05BR044:gene:NCBIGene:9415][rank:05BR044:gene:NCBIGene:79143]. Model‑ranked drugs are mostly vitamins/cofactors (Biotin, Cholic Acid, Nicotinamide) [rank:05BR044:drug:DRUGBANK:DB00121][rank:05BR044:drug:DRUGBANK:DB02659][rank:05BR044:drug:DRUGBANK:DB02701]. Curated drug‑target links identify approved RET inhibitors (Cabozantinib, Vandetanib, Lenvatinib, Sorafenib, Ponatinib) that match the *RET* mutation [E337557][E337556][E337560][E337554][E337559], AKT1 inhibitors (Arsenic trioxide) matching the *AKT1* mutation [E330776], and Biotin targeting up‑regulated MCCC1 [E330981].

**Evidence paths**
- *RET* p.G453R mutation → Cabozantinib/Vandetanib/Lenvatinib/Sorafenib/Ponatinib (drug‑protein edges) [E337557][E337556][E337560][E337554][E337559]
- *AKT1* p.E17K mutation → Arsenic trioxide (drug‑protein edge) [E330776]
- MCCC1 up‑regulation (z=5.16) → Biotin (drug‑protein edge) [E330981]
- GOT1 up‑regulation (z=4.9) → Adapalene/Cysteine (drug‑protein edges) [E331581][E331580]
- *TP53* p.R337C mutation → DisMech chain: TP53 loss of function → EMT → organ‑specific tropism → immune evasion [E8137942][E8137943][E8137935][E8137937]
- *AKT1* mutation → DisMech chain: PIK3CA/PI3K‑AKT activation → mTOR activation [E8271400][E8271401][E8271403]
- Subgraph places AKT1 in PI3K/AKT nuclear signaling and TP53 regulation [E3799141][E3799144][E3799158]; RET interacts with GDNF, FAU, KYNU, MAPK15 [E32294][E73525][E117051][E289227]; GOT1 in aspartate/glutamate metabolism [E3691511][E3762456]; P4HB in ER chaperone/VLDL assembly [E3810740][E3634749]; SCP2 in mitochondrial lipid metabolism [E3587305][E3821361].

**Mechanism**
1. TP53 loss of function drives EMT, dissemination and immune evasion in breast carcinoma [PMID:23000897][PMID:21336307].
2. PIK3CA/PI3K‑AKT pathway activation (relevant to *AKT1* p.E17K) leads to constitutive mTOR signaling [PMID:15647370].
3. ER/HER2 receptor heterogeneity underlies subtype diversity [PMID:27349894].
4. Endocrine resistance, angiogenic outgrowth and cell‑survival/proliferation pathways complete the core mechanisms [E8271407][E8137940][E8271406].

**Targets / drugs**
1. **RET inhibitors** (Cabozantinib, Vandetanib, Lenvatinib, Sorafenib, Ponatinib) – target the somatically mutated *RET* p.G453R [E337557][E337556][E337560][E337554][E337559].
2. **AKT1 inhibitors** (Arsenic trioxide; investigational: Archexin, Perifosine, Enzastaurin) – target the *AKT1* p.E17K mutation [E330776][E330780][E330782][E330781].
3. **Biotin** – targets up‑regulated MCCC1 (biotin‑dependent carboxylase) [E330981]; also model‑ranked #1 [rank:05BR044:drug:DRUGBANK:DB00121].
4. **Adapalene / Cysteine** – target up‑regulated GOT1 (aspartate aminotransferase) [E331581][E331580].
5. **Model‑ranked metabolic genes** (UGT1A6, FADS2, MBOAT7, POR) – highlight lipid‑detoxification pathways the tumor may depend on [rank:05BR044:gene:NCBIGene:54578][rank:05BR044:gene:NCBIGene:9415][rank:05BR044:gene:NCBIGene:79143][rank:05BR044:gene:NCBIGene:5447].
6. **Standard‑of‑care BRCA drugs** (Palbociclib, Fulvestrant, Elacestrant, Capivasertib, Olaparib, Talazoparib, Trastuzumab deruxtecan, Sacituzumab govitecan, Alpelisib, Inavolisib) have DisMech treatment edges to breast carcinoma [E8137916][E8137917][E8137919][E8137921][E8137924][E8137925][E8137927][E8137929][E8271390][E8271392] but no direct target match to this patient’s mutations/proteins in the graph.

**Testable hypothesis**
Hypothesis: The *RET* p.G453R and *AKT1* p.E17K co‑mutation creates a dual dependency on RET and PI3K‑AKT signaling that can be simultaneously targeted with a RET inhibitor (e.g., Cabozantinib) plus an AKT/PI3K inhibitor (e.g., Capivasertib), while Biotin supplementation may exacerbate MCCC1‑driven anaplerosis.
Experiment: Treat patient‑derived organoids or xenografts with Cabozantinib ± Capivasertib ± Biotin withdrawal; measure viability, p‑AKT, p‑RET, and MCCC1 activity.

**Caveats**
- No GNN‑A risk estimate exists for BRCA; clinical stage/grade/outcome are unknown.
- Protein z‑scores are relative to the tumor cohort (no matched normal).
- Drug‑target edges are PrimeKG links; a shared target is a rationale to investigate, not evidence of efficacy.
- Model‑ranked drugs are vitamins/cofactors scored by cohort‑relative GNN signal; clinical relevance is uncertain.
- *CD74* p.Q13R and down‑regulated proteins (NOL4L, POLK, etc.) have no connected drug/mechanism evidence in the current subgraph.

_Verifier: removed 1 claim(s) that had no supporting edge or PMID._

### Claims and what each citation is

- ✅ supported — Patient 05BR044’s tumor carries somatic mutations in *AKT1* (p.E17K), *RET* (p.G453R), *TP53* (p.R337C) and *CD74* (p.Q13R).
    - `pt:05BR044:somatic_mutation:NCBIGene:207` patient: AKT1 p.E17K (somatic)
    - `pt:05BR044:somatic_mutation:NCBIGene:5979` patient: RET p.G453R (somatic)
    - `pt:05BR044:somatic_mutation:NCBIGene:7157` patient: TP53 p.R337C (somatic)
    - `pt:05BR044:somatic_mutation:NCBIGene:972` patient: CD74 p.Q13R (somatic)
- ✅ supported — The most up‑regulated tumor proteins are SCP2, P4HB, MCCC1, GOT1 and ACSL3.
    - `pt:05BR044:protein_up:NCBIGene:6342` patient: SCP2 protein up (z=5.5)
    - `pt:05BR044:protein_up:NCBIGene:5034` patient: P4HB protein up (z=5.3)
    - `pt:05BR044:protein_up:NCBIGene:56922` patient: MCCC1 protein up (z=5.2)
    - `pt:05BR044:protein_up:NCBIGene:2805` patient: GOT1 protein up (z=4.9)
    - `pt:05BR044:protein_up:NCBIGene:2181` patient: ACSL3 protein up (z=4.8)
- ❌ removed — The GNN‑A risk model is not available for BRCA, so no stage‑III/IV probability is estimated.
- ✅ supported — Model‑ranked genes highlight lipid‑metabolism and detoxification enzymes (UGT1A6, EBPL, FADS2, MBOAT7).
    - `rank:05BR044:gene:NCBIGene:54578` model rank: UGT1A6 (#1 gene)
    - `rank:05BR044:gene:NCBIGene:84650` model rank: EBPL (#2 gene)
    - `rank:05BR044:gene:NCBIGene:9415` model rank: FADS2 (#4 gene)
    - `rank:05BR044:gene:NCBIGene:79143` model rank: MBOAT7 (#5 gene)
- ✅ supported — Model‑ranked drugs are mostly vitamins/cofactors (Biotin, Cholic Acid, Nicotinamide).
    - `rank:05BR044:drug:DRUGBANK:DB00121` model rank: Biotin (#1 drug)
    - `rank:05BR044:drug:DRUGBANK:DB02659` model rank: Cholic Acid (#2 drug)
    - `rank:05BR044:drug:DRUGBANK:DB02701` model rank: Nicotinamide (#5 drug)
- ✅ supported — Curated drug‑target links identify approved RET inhibitors (Cabozantinib, Vandetanib, Lenvatinib, Sorafenib, Ponatinib) that match the *RET* mutation, AKT1 inhibitors (Arsenic trioxide) matching the *AKT1* mutation, and Biotin targeting up‑regulated MCCC1.
    - `E337557` Cabozantinib —drug_protein→ RET
    - `E337556` Vandetanib —drug_protein→ RET
    - `E337560` Lenvatinib —drug_protein→ RET
    - `E337554` Sorafenib —drug_protein→ RET
    - `E337559` Ponatinib —drug_protein→ RET
    - `E330776` Arsenic trioxide —drug_protein→ AKT1
    - `E330981` Biotin —drug_protein→ MCCC1
- ✅ supported — *RET* p.G453R mutation → Cabozantinib/Vandetanib/Lenvatinib/Sorafenib/Ponatinib (drug‑protein edges)
    - `E337557` Cabozantinib —drug_protein→ RET
    - `E337556` Vandetanib —drug_protein→ RET
    - `E337560` Lenvatinib —drug_protein→ RET
    - `E337554` Sorafenib —drug_protein→ RET
    - `E337559` Ponatinib —drug_protein→ RET
- ✅ supported — *AKT1* p.E17K mutation → Arsenic trioxide (drug‑protein edge)
    - `E330776` Arsenic trioxide —drug_protein→ AKT1
- ✅ supported — MCCC1 up‑regulation (z=5.16) → Biotin (drug‑protein edge)
    - `E330981` Biotin —drug_protein→ MCCC1
- ✅ supported — GOT1 up‑regulation (z=4.9) → Adapalene/Cysteine (drug‑protein edges)
    - `E331581` Adapalene —drug_protein→ GOT1
    - `E331580` Cysteine —drug_protein→ GOT1
- ✅ supported — *TP53* p.R337C mutation → DisMech chain: TP53 loss of function → EMT → organ‑specific tropism → immune evasion
    - `E8137942` breast carcinoma —dm_disease_has_basis_in→ TP53 Loss of Function
    - `E8137943` TP53 Loss of Function —dm_causes→ EMT-Driven Dissemination
    - `E8137935` EMT-Driven Dissemination —dm_causes→ Organ-Specific Tropism
    - `E8137937` Organ-Specific Tropism —dm_causes→ Immune Evasion in Metastatic Niches
- ✅ supported — *AKT1* mutation → DisMech chain: PIK3CA/PI3K‑AKT activation → mTOR activation
    - `E8271400` breast carcinoma —dm_disease_has_basis_in→ PIK3CA Oncogenic Mutations
    - `E8271401` PIK3CA Oncogenic Mutations —dm_causes→ Constitutive PI3K-AKT Pathway Activation
    - `E8271403` Constitutive PI3K-AKT Pathway Activation —dm_causes→ mTOR Pathway Activation
- ✅ supported — Subgraph places AKT1 in PI3K/AKT nuclear signaling and TP53 regulation; RET interacts with GDNF, FAU, KYNU, MAPK15; GOT1 in aspartate/glutamate metabolism; P4HB in ER chaperone/VLDL assembly; SCP2 in mitochondrial lipid metabolism.
    - `E3799141` AKT1 —pathway_protein→ AKT phosphorylates targets in the nucleus
    - `E3799144` AKT1 —pathway_protein→ AKT-mediated inactivation of FOXO1A
    - `E3799158` AKT1 —pathway_protein→ Regulation of TP53 Activity through Association with Co-factors
    - `E32294` GDNF —protein_protein→ RET
    - `E73525` FAU —protein_protein→ RET
    - `E117051` RET —protein_protein→ KYNU
    - `E289227` RET —protein_protein→ MAPK15
    - `E3691511` GOT1 —bioprocess_protein→ aspartate metabolic process
    - `E3762456` GOT1 —bioprocess_protein→ glutamate catabolic process to 2-oxoglutarate
    - `E3810740` P4HB —pathway_protein→ VLDL assembly
    - `E3634749` P4HB —cellcomp_protein→ procollagen-proline 4-dioxygenase complex
    - `E3587305` SCP2 —cellcomp_protein→ mitochondrion
    - `E3821361` SCP2 —pathway_protein→ Beta-oxidation of pristanoyl-CoA
- ✅ supported — TP53 loss of function drives EMT, dissemination and immune evasion in breast carcinoma.
    - [PMID:23000897](https://pubmed.ncbi.nlm.nih.gov/23000897/)
    - [PMID:21336307](https://pubmed.ncbi.nlm.nih.gov/21336307/)
- ✅ supported — PIK3CA/PI3K‑AKT pathway activation (relevant to *AKT1* p.E17K) leads to constitutive mTOR signaling.
    - [PMID:15647370](https://pubmed.ncbi.nlm.nih.gov/15647370/)
- ✅ supported — ER/HER2 receptor heterogeneity underlies subtype diversity.
    - [PMID:27349894](https://pubmed.ncbi.nlm.nih.gov/27349894/)
- ✅ supported — Endocrine resistance, angiogenic outgrowth and cell‑survival/proliferation pathways complete the core mechanisms.
    - `E8271407` breast carcinoma —dm_disease_has_basis_in→ Endocrine Resistance
    - `E8137940` breast carcinoma —dm_disease_has_basis_in→ Angiogenic Outgrowth
    - `E8271406` breast carcinoma —dm_disease_has_basis_in→ Cell Survival and Proliferation
- ✅ supported — **RET inhibitors** (Cabozantinib, Vandetanib, Lenvatinib, Sorafenib, Ponatinib) – target the somatically mutated *RET* p.G453R.
    - `E337557` Cabozantinib —drug_protein→ RET
    - `E337556` Vandetanib —drug_protein→ RET
    - `E337560` Lenvatinib —drug_protein→ RET
    - `E337554` Sorafenib —drug_protein→ RET
    - `E337559` Ponatinib —drug_protein→ RET
- ✅ supported — **AKT1 inhibitors** (Arsenic trioxide; investigational: Archexin, Perifosine, Enzastaurin) – target the *AKT1* p.E17K mutation.
    - `E330776` Arsenic trioxide —drug_protein→ AKT1
    - `E330780` Archexin —drug_protein→ AKT1
    - `E330782` Perifosine —drug_protein→ AKT1
    - `E330781` Enzastaurin —drug_protein→ AKT1
- ✅ supported — **Biotin** – targets up‑regulated MCCC1 (biotin‑dependent carboxylase); also model‑ranked #1.
    - `E330981` Biotin —drug_protein→ MCCC1
    - `rank:05BR044:drug:DRUGBANK:DB00121` model rank: Biotin (#1 drug)
- ✅ supported — **Adapalene / Cysteine** – target up‑regulated GOT1 (aspartate aminotransferase).
    - `E331581` Adapalene —drug_protein→ GOT1
    - `E331580` Cysteine —drug_protein→ GOT1
- ✅ supported — **Model‑ranked metabolic genes** (UGT1A6, FADS2, MBOAT7, POR) – highlight lipid‑detoxification pathways the tumor may depend on.
    - `rank:05BR044:gene:NCBIGene:54578` model rank: UGT1A6 (#1 gene)
    - `rank:05BR044:gene:NCBIGene:9415` model rank: FADS2 (#4 gene)
    - `rank:05BR044:gene:NCBIGene:79143` model rank: MBOAT7 (#5 gene)
    - `rank:05BR044:gene:NCBIGene:5447` model rank: POR (#12 gene)
- ✅ supported — **Standard‑of‑care BRCA drugs** (Palbociclib, Fulvestrant, Elacestrant, Capivasertib, Olaparib, Talazoparib, Trastuzumab deruxtecan, Sacituzumab govitecan, Alpelisib, Inavolisib) have DisMech treatment edges to breast carcinoma but no direct target match to this patient’s mutations/proteins in the graph.
    - `E8137916` Palbociclib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137917` Fulvestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137919` Elacestrant —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137921` capivasertib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137924` Olaparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137925` Talazoparib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137927` Trastuzumab deruxtecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8137929` Sacituzumab govitecan —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8271390` Alpelisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
    - `E8271392` inavolisib —dm_treats_or_applied_or_studied_to_treat→ breast carcinoma
- 🟡 hypothesis — Hypothesis: The *RET* p.G453R and *AKT1* p.E17K co‑mutation creates a dual dependency on RET and PI3K‑AKT signaling that can be simultaneously targeted with a RET inhibitor (e.g., Cabozantinib) plus an AKT/PI3K inhibitor (e.g., Capivasertib), while Biotin supplementation may exacerbate MCCC1‑driven anaplerosis.
